• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MacDermid Incorporated

MacDermid Incorporated

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

    Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

  2. Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

    Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

  3. ERYTECH reports additional positive Phase III results from clinical study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia

    ERYTECH reports additional positive Phase III results from clinical study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia

  4. AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting

    AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting

  5. Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting

    Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting

  6. FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

    FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

  7. The New Tax Law and IRAs

    The 2010 "Tax Relief Act" affects planning for our clients' retirement benefits in three ways.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.